KalVista Pharmaceuticals Inc. (KALV) is all set to be acquired by Chiesi Group, an international research-focused biopharmaceutical group, for $27.00 per share in cash, representing an equity consideration of roughly $1.9 billion.
The flagship drug of KalVista is EKTERLY, the first and only oral on-demand treatment for Hereditary Angioedema (HAE). The US commercial launch of EKTERLY was initiated on July 7, 2025. The drug generated net product revenue of $49.1 million in 2025.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.